VivoSim Labs, Inc. (VIVS) Spending and interest coverage
- R&D / revenue · 12 months: Value 3857.14%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 3857.14% | Research and development expense / revenue. Period ending 2026-06-30. $4.32M ÷ $112.00K × 100 ≈ 3857.14% |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 4.32M USD | Research and Development Expense |
| Revenue | 112.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | (m) | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -11.33M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.32M | $112.00K | (m) | $-11.33M | (m) | 3857.14% | (m) | (m) | (m) |
| 2026-03-31 | $4.19M | $131.00K | (m) | $-11.49M | (m) | 3197.71% | (m) | (m) | (m) |
| 2025-12-31 | $3.92M | $142.00K | (m) | $-11.45M | (m) | 2762.68% | (m) | (m) | (m) |
| 2025-09-30 | $4.56M | $140.00K | (m) | $-12.17M | (m) | 3259.29% | (m) | (m) | (m) |
| 2025-06-30 | $4.62M | $142.00K | (m) | $-12.14M | (m) | 3256.34% | (m) | (m) | (m) |
| 2025-03-31 | $5.03M | $144.00K | (m) | $-12.62M | (m) | 3489.58% | (m) | (m) | (m) |
| 2024-12-31 | $5.23M | $122.00K | (m) | $-12.56M | (m) | 4286.07% | (m) | (m) | (m) |
| 2024-09-30 | $4.88M | $103.00K | (m) | $-12.77M | (m) | 4740.78% | (m) | (m) | (m) |
| 2024-06-30 | $5.23M | $73.00K | (m) | $-14.28M | (m) | 7169.86% | (m) | (m) | (m) |
| 2024-03-31 | $5.50M | $109.00K | (m) | $-15.09M | (m) | 5044.04% | (m) | (m) | (m) |
| 2023-12-31 | $9.88M | $242.00K | (m) | $-19.77M | (m) | 4084.30% | (m) | (m) | (m) |
| 2023-09-30 | $9.63M | $368.00K | (m) | $-19.45M | (m) | 2618.21% | (m) | (m) | (m) |
| 2023-06-30 | $9.53M | $445.00K | (m) | $-18.69M | (m) | 2141.80% | (m) | (m) | (m) |
| 2023-03-31 | $8.88M | $370.00K | (m) | $-17.73M | (m) | 2401.35% | (m) | (m) | (m) |
| 2022-12-31 | $4.57M | $1.71M | (m) | $-11.87M | (m) | 267.62% | (m) | (m) | (m) |
| 2022-09-30 | $4.31M | $1.58M | (m) | $-12.01M | (m) | 273.43% | (m) | (m) | (m) |
| 2022-06-30 | $3.76M | (m) | (m) | $-12.16M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $3.32M | $1.50M | (m) | $-11.48M | (m) | 221.33% | (m) | (m) | (m) |
| 2021-12-31 | $2.86M | (m) | (m) | $-12.16M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $2.33M | (m) | (m) | $-11.16M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $1.68M | (m) | (m) | $-16.60M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $1.10M | $0.00 | (m) | $-16.83M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $301.00K | $0.00 | (m) | $-17.12M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $44.00K | $298.00K | (m) | $-19.86M | (m) | 14.77% | (m) | (m) | (m) |
| 2020-06-30 | $1.46M | $1.53M | (m) | $-17.74M | (m) | 95.62% | (m) | (m) | (m) |
| 2020-03-31 | $5.28M | $2.20M | (m) | $-21.48M | (m) | 240.62% | (m) | (m) | (m) |
| 2019-12-31 | $9.82M | $2.88M | (m) | $-25.74M | (m) | 341.34% | (m) | (m) | (m) |
| 2019-09-30 | $13.45M | $3.36M | (m) | $-27.04M | (m) | 400.77% | (m) | (m) | (m) |
| 2019-06-30 | $15.20M | $3.07M | (m) | $-26.22M | (m) | 494.98% | (m) | (m) | (m) |
| 2019-03-31 | $14.75M | $3.09M | (m) | $-27.27M | (m) | 477.26% | (m) | (m) | (m) |
| 2018-12-31 | $14.32M | (m) | (m) | $-27.70M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $14.54M | (m) | $5.11M | $-29.08M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $16.30M | (m) | $6.13M | $-32.65M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $17.96M | (m) | $6.90M | $-35.27M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $19.52M | (m) | $7.45M | $-38.38M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $20.54M | (m) | $8.22M | $-40.10M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $20.13M | (m) | $8.02M | $-40.00M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $19.55M | (m) | $7.39M | $-38.58M | $0.00 | (m) | (m) | (m) | Reported |
| 2016-12-31 | $18.55M | (m) | $7.05M | $-36.32M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $18.11M | (m) | $8.13M | $-37.16M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $18.31M | (m) | $8.21M | $-38.96M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $18.01M | (m) | $8.56M | $-38.64M | $0.00 | (m) | (m) | (m) | Reported |
| 2015-12-31 | $17.11M | (m) | $8.85M | $-38.18M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $15.76M | (m) | $7.34M | $-34.67M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $14.25M | (m) | $7.26M | $-32.34M | $4.00K | (m) | (m) | -8086.25× | Reported |
| 2015-03-31 | $12.92M | (m) | $7.02M | $-30.30M | $1.00K | (m) | (m) | -30297.00× | Reported |
| 2014-12-31 | $11.77M | (m) | $6.97M | $-29.01M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $10.91M | $399.00K | $6.15M | $-26.68M | (m) | 2735.09% | 1540.35% | (m) | (m) |
| 2014-06-30 | $9.31M | $372.00K | $5.33M | $-23.32M | (m) | 2501.61% | 1434.14% | (m) | (m) |
| 2014-03-31 | $7.97M | $379.00K | $4.60M | $-20.65M | $13.00K | 2103.96% | 1213.72% | -1588.38× | Reported |
| 2013-12-31 | $6.87M | $479.00K | $3.69M | $-17.99M | $78.00K | 1433.82% | 769.94% | -230.60× | Reported |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $4.34M | $1.29M | $2.28M | $-12.02M | $65.00K | 335.68% | 176.39% | -184.85× | Reported |
| 2012-12-31 | $3.44M | $1.20M | $1.44M | $-9.32M | $1.09M | 287.05% | 119.88% | -8.57× | Reported |
| 2012-09-30 | (m) | $848.21K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $380.65K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $1.42M | $969.00K | $9.00K | $-2.31M | $2.07M | 146.54% | 0.93% | -1.12× | Reported |
| 2011-09-30 | (m) | $606.14K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $374.16K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $1.20M | $603.00K | $4.00K | $-1.18M | $161.00K | 199.50% | 0.66% | -7.32× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |